NVACW Profusa, Inc.

Price Chart

Executive Summary

Profusa Inc. amended its Asset Purchase Agreement with Bio Insights LLC to delete a provision that would have issued management shares equal to 12% of fully diluted common stock to the CEO and CFO upon closing. The $30 million acquisition of the PanOmics Assay platform proceeds unchanged, but the removal of this management equity grant eliminates a significant future dilution overhang for existing shareholders.

Key Financial Metrics

Actionable Insight

Key Facts

• Amendment dated May 22, 2026 removes Section 4.6 (Management Shares) from the Asset Purchase Agreement
• Previously, management would have received 12% of fully diluted shares post-closing and any related equity financing
• The $30 million aggregate purchase price for the PanOmics Assay assets remains unchanged
• Consideration is paid via Series A Convertible Preferred Stock (non-voting, convertible into common)
• All other terms of the April 21, 2026 Asset Purchase Agreement remain in full force

Financial Impact

Eliminates a 12% fully diluted share issuance to management, preserving equity value for existing shareholders. The $30 million purchase price via convertible preferred stock still creates potential future dilution upon conversion.

Risk Factors

• The $30 million Series A Convertible Preferred Stock still converts into common shares, creating dilution upon conversion
• No financial details on the PanOmics Assay's revenue or profitability were disclosed
• The ticker NVACW (warrants) may have different liquidity and risk profile than the common stock PFSA

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status

Related Tickers